This activity already occurred and is no longer available.
Clinical Updates: Technologies for Diagnosing Osteoporosis
This issue of "Osteoporosis: Clinical Updates", we will take a look at current research in the field of fracture prediction and bone quality assessment and discuss implications for osteoporosis patient care. Fee: Member- $0; Nonmember-$10
Initial Date: April 11, 2018
Expiration Date: April 30, 2020
Credits Available: 1 hour
Fee: Members-$0; Nonmembers- $10

Medical writer:                

Kelly A. Trippe, MA: No relationships to disclose

Guest reviewer:               

Avery Jackson, MD, FAANS FACS: No relationships to disclose

Lead Nurse Planner:       

Susan Randall, MSN, RN, FNP-BC: No relationships to disclose

Editors and content reviewers:

                Angelo Licata, MD, PhD:  No relationships to disclose

                Carolyn J. Bolognese, RN, CDE: No relationships to disclose

                Peggy Doheny, PhD, RN, CNS, ONC, FAAN: No relationships to disclose. 

Paul Miller, MD, FACP: Alexion: Research Support. Amgen: Consultant; Advisory Board; Research Support. Boehringer Ingelheim: Research Support. Diaachi: Research Support Immunodiagnostics: Research Support. Merck: Research Support. Merck Serono: Research Support. Novartis: Research Support. Radius: Consultant; Advisory Board; Research Support. Regeneron: Research Support. Roche Diagnostic: Research Support.

Jeri Nieves, PhD: No relationships to disclose

Mary Beth O’Connell, PharmD, BCPS: No relationships to disclose 

Rick Pope, MPAS, PA-C, DFAAPA: Faculty: Abbvie, Takeda Consultant: Medac, Sanofi-Biosurgery

Carol Sedlak, PhD, RN, CNS, ONC, CNE, FAAN: No relationships to disclose

Robert Westergan, MD: No relationships to disclose

NOF Clinical Director:

Andrea Singer, MD , FACP, CCD: Amgen: Consultant; Speakers Bureau / Teaching Engagements; Advisory Board. Eli Lilly : Consultant; Speakers Bureau / Teaching Engagements; Advisory Board. Hologic, Inc: Consultant. Medtronic: Consultant. Merck: Consultant. Radius: Consultant; Advisory Board. UCB: Consultant

For information about NOF’s Clinical Updates and its Editorial Board click here

Activity Description

Strategies to reduce fracture risk must be based on a sound understanding of the cellular, molecular, and biomechanical mechanisms that underlie the increased risk of fractures with aging. Whereas low bone mineral density (BMD) is among the strongest risk factors for fracture, a growing body of evidence demonstrates the limitations of current screening criteria and BMD measurement in targeting those at risk with fracture prevention therapy. These observations have brought renewed attention to the broader array of factors that influence fracture risk, collectively called “bone quality” and the need for better tools to measure parameters that determine skeletal strength and resistance to fracture.

This issue of "Osteoporosis: Clinical Updates" we will take a look at current research in the field of fracture prediction and bone quality assessment and discuss implications for osteoporosis patient care settings, and is uniquely suited for primary care practice.  


Intended Audience

This continuing education activity is intended for use by health professionals who participate in the care of patients at risk for or suffering from osteoporosis, in the areas of primary care, endocrinology, geriatrics, gynecology, internal medicine, obstetrics, orthopedics, osteopathy, pediatrics, physiatry, radiology, rheumatology and physical therapy.

This includes physicians, nurse practitioners, registered nurses, pharmacists, physician assistants, technologists, researchers, public health professionals and health educators with an interest in osteoporosis and bone health.


Objectives
Upon completion of this activity the participant should be able to:

  • Recognize patients at low risk for fracture despite osteopenia by BMD T-score.

    Identify patients who may benefit from non-DXA bone strength assessment.

    Explain the limitations of DXA to fully characterize bone fragility.

    Select the appropriate osteoporosis prediction tool for individual patients.

    Interpret and explain the significance of a patient’s trabecular bone score.

CME Program Eligibility
Method of Participation in the Learning Process: Clinician learners will read and analyze the subject matter, conduct additional informal research through related internet searches on the subject matter, and complete a post-test assessment of knowledge and skills gained as a result of the activity.

After participating in this activity, the reader has the option of taking a post-test with a passing grade of 70% or better to qualify for continuing education credit for this activity. It is estimated it will take 1.0 hour(s) to complete the reading and take the post-test. Continuing education credit will be available for two years from the date of publication.


Accreditation


The National Osteoporosis Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Osteop
orosis Foundation designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The National Osteoporosis Foundation is accredited as a provider of continuing
nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. The National Osteoporosis Foundation designates this educational activity for a maximum of 1.0 continuing nursing education credit(s).

Other healthcare providers will also be able to receive a certificate of completion; nurse practitioners and physician assistants may request an AMA PRA Category 1 Credit(s)™ certificate of participation.

Disclosure of Commercial Support

It is the policy of the National Osteoporosis Foundation (NOF) to ensure balance, independence, objectivity, and scientific rigor in all its sponsored publications and programs. NOF requires the disclosure of the existence of any significant financial interest or any other relationship the sponsor, Editorial Board or Guest Contributors have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. All authors and contributors to this continuing education activity have disclosed any real or apparent interest that may have direct bearing on the subject matter of this program.

Please be advised that NOF’s accreditation status with ACCME and ANCC does not imply endorsement by NOF, ACCME or ANCC of any commercial products displayed in conjunction with this activity or endorsement of any point of view.


Statement regarding OFF Label Use

Please be advised that any publication of the Osteoporosis Clinical Updates that discusses off-label use of any medications or devices will be disclosed to the participant.

Refund Policy
NOF offers no returns or refunds on online internet CME activities purchased through our store. All sales are final. Meeting and workshop registrations will be refunded in accordance with the cancellation policy of the meeting and/or workshop, as outlined at registration.


Type:     Internet Activity (Enduring Material)
31 Registered Users

National Osteoporosis Foundation

251 18th Street South, Suite 630, Arlington, VA 22202 I [p] 1 (800) 231-4222 • [f] 1 (703) 414-3742

The National Osteoporosis Foundation is a qualified 501(c)(3) tax-exempt organization and all donations to the organization are
tax deductible to the full extent allowable by law. NOF’s tax ID number is 36-3350532.